文献速递头颈与中枢神经肿瘤

Ⅱ期鼻咽癌同步放化疗与单纯放疗Ⅲ期随机试验的十年生存与毒性结局

Ten-year outcomes of survival and toxicity for a phase III randomised trial of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma.
PubMed 文献 · Eur J Cancer · 2019-02-07

这项Ⅲ期随机试验将Ⅱ期鼻咽癌患者分为单纯放疗组(114例)和同步放化疗组(116例,每周顺铂方案),中位随访125个月。同步放化疗组在总生存(83.6% vs 65.8%,P=0.001)、无进展生存、肿瘤特异性生存及无远处转移生存方面均显著优于单纯放疗组,且未增加晚期毒性。

要点

  • 同步放化疗组10年总生存83.6%,单纯放疗组65.8%(P=0.001)。
  • 同步放化疗组无进展生存76.7%,单纯放疗组64.0%(P=0.014)。
  • 同步放化疗组无远处转移生存94.0%,单纯放疗组83.3%(P=0.007)。

核心结论

  • 十年结局证实,与常规放疗相比,同步放化疗可改善Ⅱ期鼻咽癌患者的总生存,且未增加晚期毒性。

研究设计与样本

  • Ⅲ期随机试验,Ⅱ期鼻咽癌患者随机分配至单纯放疗组(n=114)或同步放化疗组(n=116),同步放化疗采用每周顺铂方案。
  • 主要终点为总生存。

主要发现

  • 中位随访125个月,同步放化疗组总生存83.6% vs 单纯放疗组65.8%(P=0.001)。
  • 同步放化疗组无进展生存76.7% vs 单纯放疗组64.0%(P=0.014)。
  • 同步放化疗组肿瘤特异性生存86.2% vs 单纯放疗组71.9%(P=0.002)。
  • 同步放化疗组无远处转移生存94.0% vs 单纯放疗组83.3%(P=0.007)。
  • 局部区域无复发生存方面,同步放化疗的影响不显著。

关键数值与推荐

  • 总生存:同步放化疗组83.6% vs 单纯放疗组65.8%(P=0.001)。
  • 无进展生存:同步放化疗组76.7% vs 单纯放疗组64.0%(P=0.014)。
  • 肿瘤特异性生存:同步放化疗组86.2% vs 单纯放疗组71.9%(P=0.002)。
  • 无远处转移生存:同步放化疗组94.0% vs 单纯放疗组83.3%(P=0.007)。

临床怎么用

  • 原文结论认为,同步放化疗可改善Ⅱ期鼻咽癌患者的总生存,且未增加晚期毒性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Our previous results showed survival benefits of concurrent chemoradiotherapy (CCRT) in treating stage II nasopharyngeal carcinoma (NPC) compared with radiotherapy (RT) alone. Here, we present the updated 10-year survival results and late toxicity profile to assess the ultimate effectiveness of concurrent chemotherapy. METHODS: Patients with stage II NPC were randomly assigned to RT arm (n = 114) or to CCRT arm (n = 116) with a concurrent weekly cisplatin regimen. The primary end-point was overall survival (OS). RESULTS: With a median follow-up of 125 months, significant improvements in OS (83.6% vs 65.8%, P = 0.001), progression-free survival (76.7% vs 64.0%, P = 0.014), cancer-specific survival (86.2% vs 71.9%, P = 0.002), distant-metastasis free survival (94.0% vs 83.3%, P = 0.007) were observed in CCRT arm. In point of locoregional-relapse free survival, the impact of CCRT was not remarkable. The findings were in accordance with our previous report. The survival benefits earned by CCRT mainly reflected in T2N1 population. Although CCRT brought more acute toxic effects (P = 0.001), as presented in previous report, the late toxicities and treatment-associated deaths events were comparable between two arms. CONCLUSIONS: Ten-year outcomes confirmed that CCRT could improve the OS of stage II patients without adding late toxicities compared with conventional RT.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Li XY, Chen QY, Sun XS, et al. Ten-year outcomes of survival and toxicity for a phase III randomised trial of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma. Eur J Cancer. 2019. PMID: 30739837. doi:10.1016/j.ejca.2018.10.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。